Portage Biotech Inc
NASDAQ:ATON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Strategic Elements Ltd
OTC:SORHF
|
AU |
|
OVB Holding AG
XETRA:O4B
|
DE |
|
G
|
Guangdong Dcenti Auto-Parts Stock Ltd Co
SSE:603335
|
CN |
Portage Biotech Inc
EPS (Diluted)
Portage Biotech Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Portage Biotech Inc
NASDAQ:ATON
|
EPS (Diluted)
-$6
|
CAGR 3-Years
-104%
|
CAGR 5-Years
-75%
|
CAGR 10-Years
-17%
|
|
Portage Biotech Inc
Glance View
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
See Also
What is Portage Biotech Inc's EPS (Diluted)?
EPS (Diluted)
-6.8
USD
Based on the financial report for Sep 30, 2025, Portage Biotech Inc's EPS (Diluted) amounts to -6.8 USD.
What is Portage Biotech Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-17%
Over the last year, the EPS (Diluted) growth was 89%. The average annual EPS (Diluted) growth rates for Portage Biotech Inc have been -104% over the past three years , -75% over the past five years , and -17% over the past ten years .
